Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advisory Committee To Decide If Azmacort, Alupent, Intal Remain "Essential" Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Pulmonary–Allergy Drugs Advisory Committee will be asked at July 14 meeting whether these and other asthma products provide an otherwise unavailable important public health benefit. Drugs using chlorofluorocarbon propellants could be delisted from essential use category if closely related non-CFC alternatives exist, even though they are not the same moiety, FDA suggests.

You may also be interested in...



FDA Advisory Committee Splits On Combivent “Essential Use” Designation

Pulmonary-Allergy Drugs Committee votes 5-5, with two abstentions, that Boehringer Ingelheim’s Combivent should retain “essential use” designation. King’s Intal gets committee nod for essential use by slim margin. Committee votes to remove essential use designation for five CFC metered-dose inhalers drugs.

FDA Advisory Committee Splits On Combivent “Essential Use” Designation

Pulmonary-Allergy Drugs Committee votes 5-5, with two abstentions, that Boehringer Ingelheim’s Combivent should retain “essential use” designation. King’s Intal gets committee nod for essential use by slim margin. Committee votes to remove essential use designation for five CFC metered-dose inhalers drugs.

CFC-Containing Albuterol Inhalers To Be Removed By 2009

FDA's final rule sets a deadline one year earlier than the latest possible date suggested in the proposed rule. Manufacturers have said that once a phase-out date was set they could build sufficient supply of ozone-friendly albuterol product within 18 months.

Topics

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel